<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04068259</url>
  </required_header>
  <id_info>
    <org_study_id>PBI-4547-CT-9-01</org_study_id>
    <secondary_id>180271</secondary_id>
    <nct_id>NCT04068259</nct_id>
  </id_info>
  <brief_title>Single Ascending Dose Study of PBI-4547 in Healthy Subjects</brief_title>
  <official_title>A Phase 1, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of PBI-4547 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ProMetic Pharma SMT Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Syneos Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>ProMetic Pharma SMT Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety, tolerability, and pharmacokinetics (PK) of PBI-4547 in
      healthy adult participants.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a first-in-human, single-ascending dose study of PBI-4547 in healthy adult
      participants. PBI-4547 is a synthetic ligand of G protein-coupled receptor (GPR)40 and GPR84,
      which have been reported to play a role in fibrosis in various animal models as well as in
      tissue culture.

      A total of 40 healthy adult participants will sequentially receive 1 of 5 doses of PBI-4547
      (Dose1, 2, 3, 4 or 5) or matching placebo, with each cohort of 8 participants randomized in a
      3:1 ratio to receive PBI-4547 or matching placebo.

      A food-effect cohort will be added after review of the PK results of at least the first dose,
      and the following 2 doses, if needed. In this cohort participants will initially receive the
      study drug under fasting conditions (Period 1) followed by the same dose after the ingestion
      of a high-fat meal (Period 2) after a 14-day washout period.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    PK data from first 3 cohorts does not support study continuation.There was no safety concerns
  </why_stopped>
  <start_date type="Actual">September 5, 2019</start_date>
  <completion_date type="Actual">October 8, 2019</completion_date>
  <primary_completion_date type="Actual">October 8, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>5-6 days</time_frame>
    <description>TEAE is any untoward medical occurrence in a subject who has been administered a pharmaceutical product or not, which does not necessarily have a causal relationship with this treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with clinically significant laboratory evaluation findings</measure>
    <time_frame>5-6 days</time_frame>
    <description>Laboratory tests for hematology, serum chemistry and urinalysis will be performed upon admission, at discharge, and at the follow-up visit (5 ± 1 day post-dose).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with clinically significant electrocardiogram (ECG) Findings</measure>
    <time_frame>5-6 days</time_frame>
    <description>Triplicate ECG will be performed upon admission, pre-dose, and approximately 1, 2, 8, and 24 hours post-dose, and at the follow-up visit (5 ± 1 day post-dose). Subjects will be continuously monitored using a Holter monitor from approximately 1 hour pre-dose until approximately 24 hours post-dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with clinically significant vital sign findings</measure>
    <time_frame>5-6 days</time_frame>
    <description>Vital signs include blood pressure, heart rate, respiratory rate, and oral body temperature will be measured upon admission, before discharge from the clinic and at the follow-up visit (5 ± 1 day post-dose).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with physical examination findings</measure>
    <time_frame>5-6 days</time_frame>
    <description>Brief physical examination will be conducted upon admission and at discharge. A complete physical examination will be conducted at screening and follow-up visit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC0-t for PBI-4547</measure>
    <time_frame>48 hours</time_frame>
    <description>Area under the concentration-time curve from time zero to the last non-zero concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-inf for PBI-4547</measure>
    <time_frame>48 hours</time_frame>
    <description>Area under the concentration-time curve from time zero to infinity (extrapolated)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax for PBI-4547</measure>
    <time_frame>48 hours</time_frame>
    <description>Maximum observed concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Residual area for PBI-4547</measure>
    <time_frame>48 hours</time_frame>
    <description>Residual area calculated as 100*(1- AUC0-t / AUC0-inf)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax for PBI-4547</measure>
    <time_frame>48 hours</time_frame>
    <description>Time of observed Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2 el for PBI-4547</measure>
    <time_frame>48 hours</time_frame>
    <description>Elimination half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kel for PBI-4547</measure>
    <time_frame>48 hours</time_frame>
    <description>Elimination rate constant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rkel for PBI-4547</measure>
    <time_frame>48 hours</time_frame>
    <description>Accumulation factor based on elimination rate constant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRT for PBI-4547</measure>
    <time_frame>48 hours</time_frame>
    <description>Mean residence time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cl/F for PBI-4547</measure>
    <time_frame>48 hours</time_frame>
    <description>Total body clearance, calculated as Dose/AUC0-inf;Cl/F normalized for subject body weight in kg will be calculated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vd/F for PBI-4547</measure>
    <time_frame>48 hours</time_frame>
    <description>Apparent volume of distribution, calculated as Dose/(Kel x AUC0-inf). Vd/F normalized for subject body weight in kg will be calculated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-t for PBI-4547 under fed condition</measure>
    <time_frame>48 hours</time_frame>
    <description>Area under the concentration-time curve from time zero to the last non-zero concentration after a high-fat diet</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-inf for PBI-4547 under fed condition</measure>
    <time_frame>48 hours</time_frame>
    <description>Area under the concentration-time curve from time zero to infinity (extrapolated) after a high-fat diet</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax for PBI-4547 under fed condition</measure>
    <time_frame>48 hours</time_frame>
    <description>Maximum observed concentration after a high-fat diet</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax for PBI-4547 under fed condition</measure>
    <time_frame>48 hours</time_frame>
    <description>Time of observed Cmax after a high-fat diet</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>Cohort 1, Dose 1 of PBI-4547 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 1 of PBI-4547 or matching Placebo tablets by mouth</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2, Dose 2 of PBI-4547 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 2 of PBI-4547 or matching Placebo tablets by mouth</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3, Dose 3 of PBI-4547 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 3 of PBI-4547 or matching Placebo tablets by mouth</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4, Dose 4 of PBI-4547 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 4 of PBI-4547 or matching Placebo tablets by mouth</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5, Dose 5 of PBI-4547 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 5 of PBI-4547 or matching Placebo tablets by mouth</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PBI-4547</intervention_name>
    <description>PBI-4547 tablet</description>
    <arm_group_label>Cohort 1, Dose 1 of PBI-4547 or Placebo</arm_group_label>
    <arm_group_label>Cohort 2, Dose 2 of PBI-4547 or Placebo</arm_group_label>
    <arm_group_label>Cohort 3, Dose 3 of PBI-4547 or Placebo</arm_group_label>
    <arm_group_label>Cohort 4, Dose 4 of PBI-4547 or Placebo</arm_group_label>
    <arm_group_label>Cohort 5, Dose 5 of PBI-4547 or Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablet</description>
    <arm_group_label>Cohort 1, Dose 1 of PBI-4547 or Placebo</arm_group_label>
    <arm_group_label>Cohort 2, Dose 2 of PBI-4547 or Placebo</arm_group_label>
    <arm_group_label>Cohort 3, Dose 3 of PBI-4547 or Placebo</arm_group_label>
    <arm_group_label>Cohort 4, Dose 4 of PBI-4547 or Placebo</arm_group_label>
    <arm_group_label>Cohort 5, Dose 5 of PBI-4547 or Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male participants or non-childbearing potential female participants, ≥18 and
             ≤55 years.

          -  Body mass index &gt; 18.5 and &lt; 30.0 kg/m^2, and body weight ≥ 50.0 kg for male
             participants and ≥ 45.0 kg for female participants.

          -  Continuous non-smoker who has not used tobacco or nicotine-containing products for at
             least 3 months prior to screening.

          -  Male participants with a pregnant partner must agree to use a condom from the first
             dosing until at least 90 days after study drug administration.

          -  Male participants must be willing not to donate sperm until 90 days after study drug
             administration.

        Exclusion Criteria:

          -  Any clinically significant abnormality or abnormal laboratory test results.

          -  An estimated glomerular filtration rate (eGFR) &lt;60 mL/min/1.73 m^2.

          -  Positive urine drug screen and history of significant drug abuse.

          -  History of significant allergic reactions to any drug.

          -  Use of any drugs known to induce or inhibit hepatic drug metabolism.

          -  Positive pregnancy test or breast-feeding participant.

          -  Clinically significant abnormalities in ECG, blood pressure, and heart rate at
             screening.

          -  History of significant alcohol abuse or regular use of alcohol.

          -  Use of medication other than topical products without significant systemic absorption.

          -  Donation of plasma.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Moran, MD</last_name>
    <role>Study Director</role>
    <affiliation>Prometic Pharma SMT Ltd.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Richard Larouche, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Syneos Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Syneos Health</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H3X 2H9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Syneos Health</name>
      <address>
        <city>Québec</city>
        <zip>G1P 0A2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Leduc M, Grouix B, Tremblay M, GervaisL, Sarra-Bournet F, Felton X, Simard J, Leblond FA, Laurin P and Gagnon L. PBI-4547 Improves Glucose Metabolism and Insulin Resistance, and Reduces Liver Damage in a High-Fat Diet Mouse Model of Obesity and Metabolic Syndrome. Diabetes 2018 Jul; 67(Supplement 1).</citation>
  </reference>
  <reference>
    <citation>Gagnon L, Laverdure A, Sarra-Bournet F, Cloutier M, Felton A, Treemblay M, Richard J, Gervais L, Laurin P, Leblond FA and Grouix B. PBI-4547 Reverses Diabetes and Metabolic Syndrome through Regulation of Lipid/Glucose Metabolism, ß-Oxidation and Fibrosis in Liver, and White Adipose Tissue in ob/ob Mice. Diabetes 2018 Jul; 67(Supplement 1).</citation>
  </reference>
  <reference>
    <citation>Sarra-Bournet F, Grouix B, Hince K, Felton A, Tremblay M, Abbott S, Duceppe JS, Zacharie B, Laurin P, Gagnon G. PBI-4547 decreases hepatic stellate cell activation via AMPK signaling pathway, and reduces fibrosis in carbon tetrachloride (CCL4)-induced hepatic fibrosis model. Journal of Hepatology 2018, 68:S365-S604.</citation>
  </reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>August 22, 2019</study_first_submitted>
  <study_first_submitted_qc>August 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2019</study_first_posted>
  <last_update_submitted>June 17, 2020</last_update_submitted>
  <last_update_submitted_qc>June 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

